Yale University Trials - LARVOL Sigma

Yale University	Welcome, Profile Billing Logout

Yale University

Welcome, Profile Billing Logout

5 Trials

Active Trials

Export

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Woods, Scott

NCT04262401: Promoting Healthy Habits in Metabolic Syndrome

Recruiting

N/A

424

Standard health coaching, Habit-focused health coaching

Habit Design, University of Washington, TriHealth Inc.

Metabolic Syndrome

04/24

12/24

NCT04338152: Family-Focused Therapy for Individuals at High Clinical Risk for Psychosis: A Confirmatory Efficacy Trial

Active, not recruiting

N/A

220

Canada, US

Family Focused Therapy for Clinical High Risk Youth (FFT-CHR), Enhanced Care (EC)

University of California, Los Angeles, National Institute of Mental Health (NIMH)

Psychotic Disorders, Prodromal Symptoms, Prodromal Schizophrenia, Psychosis, Family

06/26

12/26

AMP SCZ, NCT05905003: ® Observational Study: PREDICT-DPACC

Recruiting

N/A

2617

Europe, Canada, US, RoW

Brigham and Women's Hospital, Orygen, Yale University, National Institute of Mental Health (NIMH)

Clinical High Risk, Psychosis, Remission, Conversion

12/24

05/25

Tek, Cenk

NCT06191965: MitoQ for Early-phase Schizophrenia-spectrum Disorder and Mitochondrial Dysfunction

Not yet recruiting

2/3

100

Europe, US

MitoQ, mitoquinol mesylate, Chemical name: [10-(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl) decyl] triphenyl phosphonium mesylate, Placebo, Sugar pill

Mclean Hospital, Yale University, University of Lausanne

Schizophrenia and Related Disorders, Mitochondrial Alteration, Cognitive Impairment

01/27

Srihari, Vinod